Startup company to offer next-generation sequencing-based pharmacogenomics interpretation
ROCHESTER, Minn. — Mayo Clinic and venture catalyst Invenshure announce the launch of Oneome, a genomics interpretation company that exports Mayo’s extensive pharmacogenomics knowledge in the form of concise, actionable reports to help providers anywhere deliver the right medication at the right time.
Oneome reports will focus on providing pharmacogenomically driven guidance for medications with high levels of evidence in medical literature. Financial terms of the agreement were not disclosed. Mayo’s collaboration with Oneome is led by the Mayo Clinic Center for Individualized Medicine.
“Our own genetic makeup can have a significant impact on how our bodies process and use prescription medication, which in turn affects whether or not a drug works the way our doctor intended,” says Oneome co-founder John Logan Black, M.D., a Mayo Clinic physician and co-director of the Personalized Genomics Laboratory in Mayo's Department of Laboratory Medicine and Pathology. “We have developed sophisticated decision algorithms that can help providers use genomic testing to get their prescriptions right the first time.”
Individual patients may have minor but significant variations in hundreds of genes. Some of these can result in potentially life-threatening reactions to a medication that may be perfectly safe for most of the population, while others make prescriptions less effective. Some people, for instance, cannot process the common pain relievers codeine and tramadol, rendering the drugs ineffective against pain. Other people process the drugs too quickly, giving the patient a rapid and dangerous pulse of relief, which may result in accidental overdose. In many cases, a patient’s genomic information offers insight into how that person is likely to respond to a particular medication.
“Even some of our most widely prescribed medications don’t work the same way in every patient,” says Dr. Black. “The same dosage of warfarin can have markedly different effects in different individuals — this is why patients taking anticoagulants need routine clotting tests.”
Invenshure co-founder and Oneome CEO Troy Kopischke says combining his company’s data processing platform with Mayo’s pharmacogenomics knowledge base positions Oneome to meet a critical and untapped need in clinical care.
“We are delighted to partner with Mayo on this initiative,” says Kopischke. “Together, we expect the unique combination of our respective technologies to rapidly enable health care IT solutions that will save lives and reduce costs.”
Research and development of the algorithms come from the Mayo Clinic Department of Laboratory Medicine and Pathology and the Mayo Clinic Center for Individualized Medicine.
Dr. Black has a financial interest in Oneome and the technology described in this release. Revenue Mayo receives is used to support the clinic’s nonprofit mission in patient care, education and research.
About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, http://www.mayoclinic.org/ and newsnetwork.mayoclinic.org.
Invenshure, LLC is a technology incubator and venture catalyst formed to create and grow companies that commercialize intellectual property from leading institutions around the world. Invenshure focuses on initiatives in healthcare informatics and personalized medicine. For more information, visit Invenshure.com.
About Mayo Clinic Center for Individualized Medicine
The Mayo Clinic Center for Individualized Medicine is home to the Individualized Medicine Clinic, the world’s first integrated multidisciplinary genomics clinic, serving patients with advanced cancer and complex diagnoses. The center discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient. Visit http://mayoresearch.mayo.edu/center-for-individualized-medicine for more information.
About Mayo Clinic Department of Laboratory Medicine and Pathology
Mayo Clinic's Department of Laboratory Medicine and Pathology is one of the largest laboratory practices in the world. The department has more than 160 physicians and scientists, 3,000 specialized laboratory staff, and 61 specialty laboratories. Testing and pathology services are available to health care organizations around the world through Mayo Medical Laboratories. Revenue from this testing is used to support medical education and research at Mayo Clinic.
Sam Smith, Mayo Clinic Public Affairs, 507-284-5005, email@example.com